Antiphospholipid syndrome (APS) is an acquired thrombotic disease, characterised by arterial (ATE) and venous thromboembolism (VTE) and/or pregnancy morbidity in the presence of persistent positivity of antiphospholipid antibodies (aPL), including anti-cardiolipin (aCL) IgG/IgM, anti β2 glycoprotein I (aβ2GPI) IgG/IgM, and lupus anticoagulant (LAC) [1]. The gene discussed is CD40LG; the disease is venous thromboembolism.